v3.22.4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
Preferred Stock
Series Seed Preferred Stock
Preferred Stock
Series A preferred stock
Preferred Stock
Series A-2 preferred stock
Preferred Stock
Series A-3 preferred stock
Preferred Stock
Series CF preferred stock
Preferred Stock
Series B Preferred Stock
Common Stock
Previously Reported
Common Stock
Additional Paid-in Capital
Previously Reported
Additional Paid-in Capital
Subscription Receivable
Accumulated Deficit
Series A-3 preferred stock
Series CF preferred stock
Total
Beginning balance (in shares) at Dec. 31, 2019 20,714,518 5,654,072 5,932,742 8,223,036 126,641     6,642              
Beginning balance at Dec. 31, 2019 $ 2,071 $ 565 $ 593 $ 823 $ 12     $ 1   $ 15,486,115 $ (22,677) $ (22,617,702)     $ (7,150,199)
Issuance of Series CF preferred stock (in shares)         709,690                    
Issuance of Series CF preferred stock         $ 71         309,679         $ 309,750
Issuance of Series A-3 preferred stock (in shares)       809,294                 809,294 709,690 0
Issuance of Series A-3 preferred stock       $ 81           428,845 $ 22,677       $ 451,603
Issuance of Series B preferred stock (in shares)           20,754,717                  
Issuance of Series B preferred stock           $ 2,075       10,997,925         11,000,000
Offering costs                   (69,470)         (69,470)
Fair value of warrant issuances - venture debt                   184,191         184,191
Stock-based compensation                   144,775         144,775
Net loss                       (10,728,295)     (10,728,295)
Ending balance at Dec. 31, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 1 $ 1 $ 27,482,060 27,482,060   (33,345,997)     (5,857,645)
Ending balance (in shares) at Dec. 31, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 6,642 6,642              
Conversion of preferred stock into common stock               $ 1   27,519,036          
Stock-based compensation                   36,976         36,976
Net loss                       (3,023,935)     (3,023,935)
Ending balance at Mar. 31, 2021 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075           (36,369,932)     (8,844,604)
Ending balance (in shares) at Mar. 31, 2021 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717   6,642              
Beginning balance (in shares) at Dec. 31, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 6,642 6,642              
Beginning balance at Dec. 31, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 1 $ 1 27,482,060 27,482,060   (33,345,997)     (5,857,645)
Conversion of preferred stock into common stock                             6,293
Conversion of notes into common stock                             2,680,289
Issuance of common stock pursuant to equity line of credit                             367,996
Net loss                             (22,659,480)
Ending balance at Sep. 30, 2021               $ 11   57,468,268   (56,005,477)     1,462,801
Ending balance (in shares) at Sep. 30, 2021               126,275              
Beginning balance (in shares) at Dec. 31, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 6,642 6,642              
Beginning balance at Dec. 31, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 1 $ 1 27,482,060 27,482,060   (33,345,997)     (5,857,645)
Conversion of preferred stock into common stock $ (2,071) $ (565) $ (593) $ (904) $ (83) $ (2,075)   $ 4   6,287         6,291
Conversion of preferred stock into common stock (shares) (20,714,518) (5,654,072) (5,932,742) (9,032,330) (836,331) (20,754,717)   40,272              
Issuance of common stock in public offering               $ 2   10,000,000         10,000,002
Issuance of common stock in public offering (in shares)               24,096              
Offering costs                   (2,116,957)         (2,116,957)
Exercise of over-allotment option                   1,364,997         1,364,997
Exercise of over-allotment option (in shares)               3,614              
Conversion of notes into common stock               $ 1   2,680,288         2,680,289
Conversion of notes into common stock (in shares)               11,352              
Conversion of related party notes and payables into common stock                   257,515         257,515
Conversion of related party notes and payables into common stock (in shares)               1,524              
Warrants issued in connection with note                   501,658         501,658
Common stock and warrants issued in connection with note (in shares)               1,300              
Common stock issued in connection with business combination               $ 3   11,428,735         11,428,738
Common stock issued in connection with business combination (in shares)               32,943              
Exercise of warrants                   1,768,046         1,768,046
Exercise of warrants (in shares)               3,869              
Common stock issued pursuant to consulting agreement                   595,500         595,500
Common stock issued pursuant to consulting agreement (in shares)               2,415              
Stock-based compensation                   4,278,337         4,278,337
Stock-based compensation (Shares)               727              
Issuance of common stock pursuant to equity line of credit                   367,696         367,696
Issuance of common stock pursuant to equity line of credit (in shares)               1,264              
Net loss                       (32,357,957)     (32,357,957)
Ending balance at Dec. 31, 2021             $ 13 $ 13 58,614,160 58,614,160   (65,703,954)     (7,089,781)
Ending balance (in shares) at Dec. 31, 2021             130,018 130,017              
Beginning balance (in shares) at Mar. 31, 2021 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717   6,642              
Beginning balance at Mar. 31, 2021 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075           (36,369,932)     (8,844,604)
Conversion of preferred stock into common stock $ (2,071) $ (565) $ (593) $ (904) $ (83) $ (2,075)   $ 4   6,287          
Conversion of preferred stock into common stock (shares) (20,714,518) (5,654,072) (5,932,742) (9,032,330) (836,331) (20,754,717)   40,272              
Issuance of common stock in public offering               $ (2)   (10,000,000)         (10,000,002)
Issuance of common stock in public offering (in shares)               24,096              
Offering costs                   (2,116,957)         (2,116,957)
Exercise of over-allotment option                   1,364,997         1,364,997
Exercise of over-allotment option (in shares)               3,614              
Conversion of notes into common stock               $ 1   2,680,288         2,680,289
Conversion of related party notes and payables into common stock                   257,515         257,515
Conversion of related party notes and payables into common stock (in shares)               1,524              
Warrants issued in connection with note                   73,958         73,958
Common stock and warrants issued in connection with note (in shares)               200              
Common stock issued in connection with business combination               $ 2   8,025,540         8,025,542
Common stock issued in connection with business combination (in shares)               21,928              
Exercise of warrants                   145,696         145,696
Exercise of warrants (in shares)               319              
Common stock issued pursuant to consulting agreement                   183,000         183,000
Common stock issued pursuant to consulting agreement (in shares)               500              
Stock-based compensation                   3,801,553         3,801,553
Net loss                       (10,697,498)     (10,697,498)
Ending balance at Jun. 30, 2021               $ 10   51,940,914   (47,067,430)     4,873,493
Ending balance (in shares) at Jun. 30, 2021               110,446              
Issuance of common stock in public offering                   367,696         367,696
Issuance of common stock in public offering (in shares)               1,264              
Common stock issued in connection with business combination               $ 1   3,403,195         3,403,196
Common stock issued in connection with business combination (in shares)               11,015              
Exercise of warrants                   1,622,350         1,622,350
Exercise of warrants (in shares)               3,550              
Stock-based compensation                   134,113         134,113
Net loss                       (8,938,047)     (8,938,047)
Ending balance at Sep. 30, 2021               $ 11   57,468,268   (56,005,477)     1,462,801
Ending balance (in shares) at Sep. 30, 2021               126,275              
Beginning balance (in shares) at Dec. 31, 2021             130,018 130,017              
Beginning balance at Dec. 31, 2021             $ 13 $ 13 58,614,160 58,614,160   (65,703,954)     (7,089,781)
Stock-based compensation                   139,093         139,093
Net loss                       (7,832,942)     (7,832,942)
Ending balance at Mar. 31, 2022               $ 14   59,954,834   (73,536,896)     (13,582,048)
Ending balance (in shares) at Mar. 31, 2022               138,756              
Beginning balance (in shares) at Dec. 31, 2021             130,018 130,017              
Beginning balance at Dec. 31, 2021             $ 13 $ 13 $ 58,614,160 58,614,160   (65,703,954)     (7,089,781)
Conversion of notes into common stock                             1,802,372
Net loss                             (22,261,338)
Ending balance at Sep. 30, 2022               $ 53   75,440,940   (87,965,292)     (12,524,298)
Ending balance (in shares) at Sep. 30, 2022   1           529,492              
Beginning balance (in shares) at Mar. 31, 2022               138,756              
Beginning balance at Mar. 31, 2022               $ 14   59,954,834   (73,536,896)     (13,582,048)
Issuance of common stock in public offering               $ (37)   (9,347,413)         (9,347,450)
Issuance of common stock in public offering (in shares)               373,898              
Offering costs                   (1,930,486)         (1,930,486)
Stock-based compensation                   119,759         119,759
Net loss                       (9,533,924)     (9,533,924)
Ending balance at Jun. 30, 2022               $ 53   68,190,549   (83,070,820)     (14,880,218)
Ending balance (in shares) at Jun. 30, 2022               528,742              
Common stock issued pursuant to consulting agreement                   123,000         123,000
Common stock issued pursuant to consulting agreement (in shares)               750              
Stock-based compensation                   110,093         110,093
Net loss                       (4,894,472)     (4,894,472)
Ending balance at Sep. 30, 2022               $ 53   $ 75,440,940   $ (87,965,292)     $ (12,524,298)
Ending balance (in shares) at Sep. 30, 2022   1           529,492